Matthew Kaplan

Stock Analyst at Ladenburg Thalmann

(2.82)
# 1,921
Out of 5,090 analysts
26
Total ratings
62.5%
Success rate
19%
Average return

Stocks Rated by Matthew Kaplan

United Therapeutics
Oct 31, 2024
Maintains: Buy
Price Target: $319$344
Current: $489.31
Upside: -29.70%
UroGen Pharma
Jun 14, 2024
Maintains: Buy
Price Target: $48$54
Current: $22.98
Upside: +132.81%
TG Therapeutics
May 2, 2024
Maintains: Buy
Price Target: $39$40
Current: $30.76
Upside: +30.04%
Liquidia
Dec 21, 2023
Maintains: Buy
Price Target: $15$30
Current: $34.41
Upside: -12.82%
Ardelyx
Aug 3, 2023
Maintains: Buy
Price Target: $7.5$8.5
Current: $5.98
Upside: +42.14%
Avadel Pharmaceuticals
May 2, 2023
Maintains: Buy
Price Target: $15$16
Current: $21.34
Upside: -25.02%
Kiora Pharmaceuticals
Feb 8, 2023
Reiterates: Buy
Price Target: $1,071
Current: $2.03
Upside: +52,658.62%
Beyond Air
Jun 29, 2022
Maintains: Buy
Price Target: $340$460
Current: $1.15
Upside: +39,900.00%
Lipocine
Dec 10, 2020
Upgrades: Buy
Price Target: $51
Current: $3.15
Upside: +1,519.05%
Cogent Biosciences
Oct 14, 2020
Initiates: Buy
Price Target: $16
Current: $38.77
Upside: -58.73%
Initiates: Buy
Price Target: $45
Current: $5.58
Upside: +706.45%